-
Rat Anti-Mouse VEGFR-2/Flk-1
Rat Anti-Mouse VEGFR-2/Flk-1
- 中文名称：
- Rat Anti-Mouse VEGFR-2/Flk-1
- 英文名称：
- Rat Anti-Mouse VEGFR-2/Flk-1
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA79111
- 规格：
- 0.05 mg|2x0.05 mg|3x0.05 mg|4x0.05 mg|5x0.05 mg
- 保存建议：
- The lyophilized antibody is stable at room temperature for up to 1 month. The reconstituted antibody is stable for at least two weeks at 2-8 degree C. Frozen aliquots are stable for at least 6 months when stored at -20 degree C.
- 货期：
- 6-8周
- 来源宿主：
- Rat
- 反应种属：
- Mouse
- 应用：
- WB (Western Blot)
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 其他：
克隆性:Monoclonal
同型:IgG1
克隆号:[IgG; 3C8]
特异性:The unconjugated antibody will detect native mouse VEGFR-2/Flk-1 in Western analysis.
纯度:Protein G purified
形式：Lyophilized
浓度：N/A
- 说明书：
Disruption of the precise balance of positi ve and negative molecular regulators of blood and lymphatic vesse l growth can lead to myriad diseases. Although dozens of natural inhibitors of hemangiogenesis have been identified, an endogenous selective inhibitor of lymphatic vesse l growth has not to our knowledge been previou sly described. A splice variant of the gene encoding vascular endothelial growth factor receptor-2 (VEGFR-2) that encodes a secreted form of the protein. designated endogenous soluble VEGFR-2 (esV EG FR- 2/KDR) has been described. The endogenous soluble esKDR inhibits developmental and reparative Iymphangiogenes is by blocking VEGF-C fun ction. Tissue-specific loss ofesKDR in mice induced, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting blood vasculature. Administration of esKDR inhibited Iymphangiogenesis but not hemangiogenesis induced by corneal suture injlllY or tran splantation, enhanced corneal allograft survival and suppressed lymphangioma cellular proliferation. Naturally occurring esKDR thus acts as a molecular uncoupler of blood and lymphatic vessels; modulation of esKDR might have therapeutic effects in treating lymphatic vascular malformations, transplantation rejection and potentially, tumor lymphangiogenesis and lymphedema.
